BU-NOT-SET CONTACT US All20252024202320222021 June 13 2024 MARBIO receives new grant funding April 02 2024 Recipharm strengthens its competitiveness by focusing on leading, core CDMO segments April 02 2024 Bespak confirms completion of inhaled and nasal drug delivery business separation from Recipharm March 26 2024 Recipharm attains major sustainability milestones March 13 2024 ReciBioPharm and GeneVentiv Therapeutics partner to advance first AAV-based gene therapy for haemophilia patients with inhibitors January 23 2024 Recipharm, Medspray, and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology December 19 2023 Recipharm harmonizes its global quality operations with Veeva Vault Quality December 11 2023 ReciBioPharm partners with Acuitas Therapeutics to provide rapid technology transfers and CGMP manufacture of Acuitas' LNP formulations November 21 2023 Marc Funk to transition to Recipharm's Board of Directors; Greg Behar appointed new CEO; Inhaled Business to standalone in 2024 November 21 2023 Recipharm annonce cesser ses activités mi-2025 sur son site de Monts, France, et va déployer ses efforts pour la recherche d'un repreneur Pagination First page Previous page Page 1 Current page 2 Page 3 Page 4 … Next page Last page
